全文获取类型
收费全文 | 2864889篇 |
免费 | 224086篇 |
国内免费 | 5221篇 |
专业分类
耳鼻咽喉 | 41060篇 |
儿科学 | 89638篇 |
妇产科学 | 74973篇 |
基础医学 | 413225篇 |
口腔科学 | 81975篇 |
临床医学 | 261560篇 |
内科学 | 554702篇 |
皮肤病学 | 59416篇 |
神经病学 | 232966篇 |
特种医学 | 113016篇 |
外国民族医学 | 946篇 |
外科学 | 431937篇 |
综合类 | 66940篇 |
现状与发展 | 3篇 |
一般理论 | 1096篇 |
预防医学 | 227881篇 |
眼科学 | 67531篇 |
药学 | 216098篇 |
7篇 | |
中国医学 | 6179篇 |
肿瘤学 | 153047篇 |
出版年
2018年 | 29416篇 |
2017年 | 22707篇 |
2016年 | 25116篇 |
2015年 | 28310篇 |
2014年 | 40316篇 |
2013年 | 61305篇 |
2012年 | 82443篇 |
2011年 | 87119篇 |
2010年 | 51312篇 |
2009年 | 48900篇 |
2008年 | 82334篇 |
2007年 | 88018篇 |
2006年 | 89004篇 |
2005年 | 86057篇 |
2004年 | 83149篇 |
2003年 | 79994篇 |
2002年 | 78902篇 |
2001年 | 134734篇 |
2000年 | 139031篇 |
1999年 | 117106篇 |
1998年 | 33201篇 |
1997年 | 29898篇 |
1996年 | 29865篇 |
1995年 | 28739篇 |
1994年 | 26941篇 |
1993年 | 25095篇 |
1992年 | 94261篇 |
1991年 | 91589篇 |
1990年 | 88773篇 |
1989年 | 85835篇 |
1988年 | 79574篇 |
1987年 | 78186篇 |
1986年 | 74130篇 |
1985年 | 70483篇 |
1984年 | 53132篇 |
1983年 | 45176篇 |
1982年 | 26993篇 |
1981年 | 24075篇 |
1979年 | 49684篇 |
1978年 | 34975篇 |
1977年 | 29438篇 |
1976年 | 27860篇 |
1975年 | 29578篇 |
1974年 | 36181篇 |
1973年 | 34314篇 |
1972年 | 32232篇 |
1971年 | 29732篇 |
1970年 | 28118篇 |
1969年 | 26128篇 |
1968年 | 23795篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Dynamic LVOT Obstruction and Aortic Stenosis in the Same Patient: A Case of Challenging Doppler Hemodynamics 下载免费PDF全文
Matthew W. Parker M.D. Francis J. Kiernan M.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(6):1030-1032
We present a patient with both dynamic left ventricular outflow tract obstruction and valvular aortic stenosis. The aortic valve was calcified, and velocities and gradients measured by continuous‐wave Doppler met standard criteria for severe aortic stenosis. The increased subvalvular velocities invalidated assumptions of the simplified Bernoulli equation; correction using the longer form of the Bernoulli equation suggested a lower but still significant gradient. The complex shape of the subvalvular spectral Doppler envelope indicated supranormal systolic function and dynamic left ventricular outflow obstruction. Left heart catheterization with an end‐hole catheter was required to determine the subvalvular and valvular components of the obstruction. 相似文献
92.
93.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
94.
95.
96.
97.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
98.
99.
Context Withania somnifera (L.) Dunal is traditionally used for treating various ailments, but lacks scientific evaluation.Objective This study evaluates Withania somnifera (WS) for its effect on platelet activity and inflammatory enzymes.Materials and methods Aqueous and ethanolic (1:1) leaf extracts were subjected to in vitro indirect haemolytic activity using Naja naja venom, human platelet aggregation was quantified for lipid peroxidation using arachidonic acid (AA) as agonist and 5-lipoxygenase (5-LOX) levels were determined using standard spectrometric assays. Further, molecular docking was performed by the ligand fit method using molegro software package (Molegro ApS, Aarhus, Denmark).Results The study found that aqueous and ethanol extracts have very negligible effect (15%) with an IC50 value of 13.8?mg/mL on PLA2 from Naja naja venom. Further, extracts of WS also had very little effect (18%) with an IC50 value of 16.6?mg/mL on malondialdehyde (MDA) formation. However, a 65% inhibition of 5-LOX with an IC50 value of 0.92?mg/mL was observed in 1:1 ethanol extracts. The same was evident from SAR model with the active ingredient withaferin A binding predominantly on Phe 77, Tyr 98, Arg 99, Asp 164, Leu 168, Ser 382, Arg 395, Tyr 396 and Tyr 614 with an atomic contact energy value of??128.96 compared to standard phenidone (?103.61). Thus, the current study validates the application of WS for inflammatory diseases.Conclusion This study reveals the inhibitory potential of W. somnifera on inflammatory enzymes and platelet aggregation. Thus, WS can serve as a newer, safer and affordable medicine for inflammatory diseases. 相似文献
100.